Archive | Redefining Early Stage Investments (RESI) RSS feed for this section

RESI Returns to Boston Next Week!

15 Sep

By Rory McCann, Director of Marketing & Conference Producer, LSN

RESI Boston is merely days away and the return to in-person events (not to mention RESI’s hometown) elicits a buzz that must be seen to be believed! Hosted in-person September 21-22 at the Westin Copley Place Hotel and virtually September 23, the hybrid format is designed to meet the unique needs of the global RESI community with the high-quality panels, pitching, and partnering experience expected from a decade of success. There is still time to register for a hybrid or virtual experience to book meetings with 800+ investors, strategic partners, service providers, tech hubs, and innovators across drugs, devices, diagnostics, and digital health. RESI is the premier partnering experience exclusively serving early-stage life science and healthcare. Be a part of history and join us for our first in-person event in more than two years.  Check out the RESI Boston 2022 Program Guide to learn more about next week’s lineup of events, speakers, pitching companies, and more!


Meet the Innovator’s Pitch Challenge Judges

15 Sep

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN


Next week’s RESI Boston will showcase 50+ Innovator’s Pitch Challenge (IPC) finalists across therapeutics, medical devices, diagnostics, digital health, and more. These companies will pitch in a live session with a panel of investor and industry expert judges and engage in Q&A. We are thankful for all the judges who will be participating and providing valuable feedback and questions to the IPC finalist companies.

Whether you are an actively fundraising early-stage company, or an active investor/strategic partner looking for targeted deal-flow, it is still not too late to register, engage in partnering meetings with attendees of interest, and join our robust program of investor panels, workshops, and pitch sessions. Below is a splash of participating judges. See you all next week!

Featured IPC Judges

Christopher Aleong
Managing Director, North America
BioEngine Capital

Paula Andrea Lengerke Diaz
Desert Angels

Sujuan Ba
President and COO
NFCR Oncology Impact Partners

Joshua Barney
Barrington Angels

Jay Batchu

Irene Blat
Sr. Dir. Search & Evaluation, Oncology

Katie Bodner Spielberg
5AM Ventures

Bruce Cohen
Venture Partner
Xeraya Capital

Ronald Dorenbos
Executive Director, Business Development, Logica
Charles River Laboratories

Aleks Engel
Partner, Novo Holdings and Director, REPAIR Impact Fund
Novo Holdings A/S

Poorya Hosseini
Camford Capital

Tomoko Ishikura
Kicker Ventures

Hanuman Jampani
Founder & President
Samrus International

Rick Jones

Deb Kemper
Managing Director
Golden Seeds

Kristin King
Boston Harbor Angels

James Lee
Investment Director
Photon Fund

Seo Lee
SV Investment

Nancy Levy
Founder and Managing Partner
BioHealth Management, LLC

Elliot Levy
Senior Associate – Healthtech
DreamIt Health

Bo Liang
Founding Partner
Alpha Bioventure

Yuwen Liu
Founding Partner
Bohe Angel Fund

Alyssa Reisner
Director & Principal
CVS Health Ventures

Ronak Savla
Director, Strategic Ventures
Catalent Strategic Ventures

Siyu Shi
F-Prime Capital

Christopher Tan
Director, Search & Evaluation, Neuroscience and Infectious Diseases & Vaccines
Merck & Co., Inc.

Jingjing Wang
Senior Associate
Lightstone Ventures

Sally Wang
Venture Partner
Viva BioInnovator

Tad Weems
Managing Director
Agilent Technologies

Matt Weinberg
Max Ventures

Ryan Witt
Tech Coast Angels

Jacqueline Young
500 Global

Z Haroon
Chairman & General Partner
Julz Co


RESI Boston Sponsors Offer Insight & Highlight Innovation

15 Sep

By Candice He, Vice President of Business Development, Global Investment Strategist, LSN

The RESI community is built up of powerful players and innovators in the early-stage life science and healthcare arena, and Life Science Nation (LSN) welcomes them back to an in-person RESI next week at the Westin Copley Place Hotel in Boston, MA. We are pleased to highlight our sponsors, not only for their impact on the quality of meetings and partnering but also for their insights and opportunities presented through their panels and workshops. Check out who will be presenting at RESI Boston next week and learn how you can get involved.

Wednesday, September 21, 11 AM EDT

Negotiating Term Sheets Workshop: What’s Best for the Company and What’s Best for You?

Matthias Breugelmans, CEO, Elastrin Therapeutics Inc.
Nancy Briefs, President & CEO, AltrixBio, Inc.
David Hendren, Managing Director, Augmentum Ventures
Mark Mihanovic, Partner, McDermott Will & Emery
Richard Smith, Counsel, McDermott Will & Emery

This interactive workshop, organized and led by McDermott Will & Emery, will provide wisdom to early-stage CEOs and management on the latest trends in term sheets, with a focus on founder and management equity opportunities. The workshop will cover common issues of concern to entrepreneurs (valuation/dilution, liquidation preference, board makeup, protective provisions, anti-dilution). Experts from the legal, investment and entrepreneurial community will discuss the interplay of financing milestones in the term sheet discussion.

Wednesday, September 21, 1 PM EDT

Shinhan Square (S2) Bridge: Showcasing Innovative Technologies from South Korea
With the motto of “One Place, One Platform”, Shinhan Square Bridge (S2 Bridge) Incheon is a platform that supports the growth of startups in cooperation with government agencies and the private sector. S2 Bridge was established as the first public-private Startup Acceleration Platform in South Korea, with the dream of becoming a global startup innovation growth hub. S2 Bridge Incheon is a proud Gold Sponsor of RESI Boston 2022, and we are excited to showcase 7 promising early-stage companies representing a wide variety of life science & healthcare technologies.

Wednesday, September 21, 3 PM EDT

Leveraging IP for Growing an Investable MedTech Company
Bryan Stewart Partner, Husch Blackwell (Moderator)
Cambre Kelly, PhD, Co-Founder & CEO, Reselute; Co-Founder & Vice President, Research & Technology restor3d
Adam T.C. Steege, Founder & President, Trio Labs
Timothy J. Skapek, CTO & Co-Founder, Protect3d
This panel for industry leaders, entrepreneurs, general counsel, and investors explores how investable healthcare entities leverage intellectual property (IP) to drive growth. Hear from medtech entrepreneurs about their experiences with IP strategy, protection, licensing, and marketing, and how these and other factors have impacted success.

In addition to these events, LSN is also pleased to offer a series of entrepreneurial workshops to tackle the nuts and bolts of building a brand and message, learning to tell your company story through these modalities, and sourcing a global target list.

Thursday, September 22, 11 AM EDT

Branding & Messaging
Claire (Chae-Kyeong) Jeong, Vice President, Investor Research & Asia Business Development, Life Science Nation
Candice He, Vice President, Business Development & Global Investment Strategist, Life Science Nation

The Branding & Messaging workshop discusses how to brand you and your firm and how to provide potential investors with high-quality, professional collateral—materials that engage them, communicate your message clearly and concisely, and present the information they want to see in a way that helps them to decide quickly and easily if you are a potential fit for their needs.

Thursday, September 22, 1 PM EDT

It All Starts with Your Story
Dennis Ford, Founder & CEO, Life Science Nation
Alex Vassallo, Business Development Manager West Coast, Entrepreneurial Education Lead, Life Science Nation

The most successful entrepreneurs are always the best storytellers. Finding a way to naturally formulate your company’s unique story and portraying this through multiple modalities whether it be a 1-minute elevator pitch or a 12-slide pitch deck is one of the most effective ways to get potential investors and partners on board with your value proposition. This bootcamp will cover the importance of entrepreneurial agency, finding your voice and developing a compelling narrative for the different players that will emerge along a deal chain, and language tools to refine your hook. Investors always bet on the team, not just the technology, and if every member of your startup can tell any strategic partner a consistent story of your company and technology, you are on the right track to building successful relationships.

Thursday, September 22, 13 PM EDT

Identifying Your Global Target List
Gregory Mannix, Vice President, International Business Development, Life Science Nation
Karen Deyo, Director of Research, Israel Business Development, Life Science Nation

The Fundraising Boot Camp provides a top-to-bottom master class on outbound global fundraising. Topics to be covered include the changing investor landscape, new categories of life science investors, and how to organize and execute a successful roadshow. It will bring you step-by-step through the processes of positioning, marketing collateral, website creation, branding & messaging, and how to reach out to a list of global investors


A Message from the Creator of RESI

14 Sep

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

DF-News-09142022Today, I am pleased to release the RESI Boston Program Guide, a momentous symbol for Life Science Nation and the RESI community as it signifies our return to onsite events since January 2020. This hybrid event takes place at the Westin Copley Place Hotel September 21-22, followed by virtual partnering September 23. The players attending RESI Boston represent the leaders, innovators, and who’s-who of early-stage drugs, devices, diagnostics and digital health (the 4 Ds).

I am grateful and proud of the effort made by the LSN team to get us back live. This Program Guide is a snapshot of the early-stage life science industry in 2022. It is not too late to attend if you are seeking capital investment or licensing opportunities. We hope to see you next week!


Join the Conversation at RESI

8 Sep

By Caitlin Dolegowski, Marketing Specialist, LSN

The Redefining Early Stage Investments (RESI) conference series is returning to Boston in T-minus two weeks! This conference will be a hybrid event taking place onsite September 21-22, with an additional day of virtual partnering Friday, September 23. The excitement of our first in-person event in over two years is compounded by the list of panelists featured at RESI Boston. Panels are crafted with the early-stage, life science entrepreneur at the forefront and the line-up at RESI Boston will be teeming with valuable content, insights, and takeaways for our attendees. Panelists will consist of investors, industry experts, and seasoned entrepreneurs covering trending topics that provide insight to fundraising startups across the silos of drugs, devices, diagnostics, and digital health (4Ds). Our panels will be live and in-person at RESI Boston with recordings available to our virtual attendees via the live agenda.

There is still time to sign up for RESI Boston! Register today to begin partnering with these innovators and more!

September 21 – 9 AM
Angels Panel

Explaining the Process of Engagement

Charles Cameron
Founder & Managing Director
Hub Angels Investment Group

Elizabeth Cho-Fertikh
Co-Founder & Managing Director
Meda Angels

Dave Fogel
Member of Screening & Due Diligence Committees
Mass Medical Angels

Wei Tao
Board Director & Chair, Bio/Genomics
Life Science Angels

September 21 – 10 AM
Medical Devices Panel

Investing in Novel Engineering

Sam Goldberger
Co-Founder & Managing Partner
Ambit Health Ventures

Z Haroon
Chairman & General Partner
Julz Co.

Kristin King
Boston Harbor Angels

Brock Reeve
Co-Founder & CEO
Eos BioInnovation

Maria Shepherd
Founder & CEO

September 21 – 11 AM
Tales from the Road Panel

The Fundraising Biotech Founder

Auriane Gamelin, MBA
Co-Founder & COO

Collin Horner
Co-Founder & CBO
Cura Therapeutics

Stanley Kim
Co-Founder & CEO
WinSanTor Bio

John Ramunas, PhD
Co-Founder & CEO
Rejuvenation Technologies

Courtney Young
Co-Founder & CEO
MyoGene Bio

September 21 – 1 PM
Diagnostics Panel

Next-Gen Tech Changing Treatment Paradigms

Tom Miller 
Managing Partner
GreyBird Ventures

Bruce Cohen
Xeraya Capital

Alex de Winter
Vice President, New Ventures
Danaher Corporation

Josh Phillips
Founder & Managing Partner
Catalyst Health Ventures 

Shuo Huang
Senior Investment Manager
Baidu Ventures

September 21 – 2 PM
Tales from the Road Panel

AI at the Intersection of Health & Tech

Robert Quinn
Co-Founder & CEO
Patchd Medical

Alicia Chong Rodriguez
Founder & CEO
Bloomer Tech 

Jessica Gibson
President & CEO
Ariel Precision Medicine

Nan-Wei Gong, PhD

Jinwoo Kim, PhD
Founder & CEO
HAII Therapeutics 

September 21 – 3 PM
New, Now, and Next in Longevity Investment Panel

Opportunities & Priorities in Age-Tech

Joshua Barney, JD 
Barrington Angels

Moshe Bellows, JD
General Partner
Maccabee Ventures

Lisa Fabiny-Kiser, MBA
SENS Research Foundation

Ray Jang, MBA
Senior Associate
Primetime Partners

Jenny Poth
Vice President, Proprietary Investments
Ziegler LinkAge

September 21 – 4 PM
Family Offices Panel

Perspectives on Seed & Series A Rounds

Catherine Zhang 
Partner & Management Committee
Kajko, Weisman & Colasanti, LLP

Sherry Grisewood
Senior Investment Officer
FoxHill Asset Management

Ron Paliwoda
Founder & President
Paliwoda Group

September 22 – 9 AM
Digital Health Panel

Leveraging Software, Lowering Costs & Improving Care

Arianne Kidder
Seae Ventures

Tomoko Ishikura
Kicker Ventures

Vic Lanio
Flare Capital Partners

Cyril Philip
Vice President, Digital Ventures
Bon Secours Mercy Health

Matt Weinberg
Max Ventures

September 22 – 10 AM
Big Pharma Panel

Strategies for Preclinical & Early Clinical Assets

Steve Cohen
Executive Director, Translational Medicine-Oncology & Internal Medicine, & Search & Evaluation
Daiichi Sankyo

Jennifer Ma
Executive Director, Business Development & Licensing

Jim MacKrell
Associate Vice President & Head, Boston Venture Science Team
Eli Lilly

Imran Nasrullah
Vice President & Head, Collaborate2Cure Hub US, Business Development & Licensing

September 22 – 11 AM
Tales from the Road Panel

Medtech Startups Redefining Possibility

Maria Shepherd
President & CEO

Angie Conley

Michael Finkelstein
Vice President, Research & Strategy
Neuro20 Technologies

Brian Hess

David Robertson
Asyst Medical

September 22 – 1 PM
Corporate VC Panel

The Changing Landscape & New Opportunities

Andy Merken
Partner, Corporate & Securities Co-Chair, Life Sciences
Burns & Levinson

Rowan Cade
Program Manager
BARDA Ventures (Division of Research Innovation and Ventures (DRIVe))

Adam Kundzewicz
Executive Director
Boehringer Ingelheim Venture Fund

Jasmina Marjanovic
AbbVie Ventures

Ronak Salva
Director, Strategic Ventures
Catalent Strategic Ventures

September 22 – 2 PM
AI Healthcare Investments Panel

Defining Tech and Discovering Potential

Wasim Q. Malik, PhD
Managing Partner
Iaso Ventures

Lana Caron, MBA
Managing Partner & Innovation Lead
Philips Ventures 

Poorya Hosseini, PhD
Camford Capital 

Lu Zhang
Managing Partner
Fusion Fund 

September 22 – 3 PM
Tales from the Road Panel

Age-Tech Innovators on Their Fundraising Journey

Steve Weissblum, MBA
Mentor-in-Residence, Techstars Future of Longevity Accelerator

Wendy Bronfin

Anthony DePasqua, MBA
EnClear Therapies

Chekesha Kidd, MBA, MHSA
Senior Health & Wellness Executive

Sam Yang
Managing Director & Co-Founder
Xandar Kardian

September 22 – 4 PM
Oncology Innovation Panel

The Search for New Approaches to Diagnosing & Treating Cancer

Kalyan Chakravarthy
Senior Manager, External Innovation

Miles Gerson
Senior Investment Director & Partner
Takeda Ventures

Andrew Meadow
General Partner
Health Innovation Capital

Atul Varadhachary
Managing Partner
Fannin Innovation Studio


The Global Tech Hub Gathering in Boston

8 Sep

By Erika Wu, Business Development Manager, Global Tech Hubs, LSN

Tech hubs from around the world are coming to RESI Boston! Tech hubs are a crucial part of the Life Science Nation (LSN) and RESI community as they provide capital, entrepreneurial support, lab space, and economic development for their cohort of aspiring scientist-entrepreneurs, and fundraising executives. With this immense support from tech hubs, their group of startups who’ve raised less than $2M USD can accelerate their entrepreneurship journey by participating in RESI at a discounted rate and taking advantage of LSN services. Ranging from universities, non-profits, incubators, accelerators, and regional and government organizations, they are all looking to connect with investors, strategic partners, and early-stage life science startups in Boston. Get to know these global communities of innovation!

Don’t see your organization on this list? Contact us to learn more about special offers for you and your constituents!

National Institute on Aging (NIA)


Shinhan Square (S2) Bridge Partnership: 7 Korean Companies Pitching at RESI Boston

8 Sep

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN


For the upcoming Redefining Early Stage Investments (RESI) conference in Boston taking place September 21-22, with an additional day for virtual partnering on September 23, Life Science Nation (LSN) is working with Shinhan Square Bridge (S2 Bridge), a Startup Acceleration Platform based in Songdo, Incheon Metropolitan City in South Korea. LSN and S2 Bridge selected seven life science companies from a competitive pool of biotech and healthcare companies that are currently in their cohort. We are excited to continue supporting the global expansion of Korean companies through RESI and look forward to their participation in only two weeks!

These companies will be presenting during a sponsored two-hour pitch session on Wednesday, September 21, 1:00 – 3:00 PM EDT, and will exhibit their posters in the exhibition hall during the two in-person days of RESI. Please RSVP here to join! If you are interested in learning more about this session, please contact me here.

Get to know the seven presenting companies:


RudaCure is a clinical stage bio-pharmaceutical start-up founded in 2018 and based in South Korea that is developing medicines for incurable diseases based on the most advanced life-science technologies to help improve human lives. By developing treatment techniques for intractable and incurable diseases, RudaCure will solve its unmet needs and treat the physical and mental pain for patients suffering from them. With creative pharmaceutical development and biomedical research, RudaCure is on the path to grow into a global pharmaceutical company.

Current main products in development include RCI001 for dry eye disease, which is in pre-IND phase and awaiting to start Phase II FDA clinical trials next year. RudaCure also plan to secure additional indications for RCI001 including conjunctivitis, keratitis and corneal ulcers. Second in development is RCI002, which is a non-opioid treatment for neuropathic and chronic pain currently in optimization stage. Other early-stage products in development include treatments for atopic dermatitis, metastasis and CRPS.

Since April of 2021, RudaCure has successfully licensed-out RCI001 to Hanlim Pharm for domestic rights in a $12M deal and is currently looking for more investors and partners to license-out for international markets. Helping RudaCure along the way, are start-up accelerators MassChallenge and Shihan Square Bridge, which are both helping RudaCure enter the US market.


Based on the research results of Professor Sang Sun Yoon’s laboratory at Yonsei University College of Medicine, BioMe Inc. was established as a faculty start-up with the aim of developing Live Biotherapeutic Products derived from human microbiome.

Through research over the past 10 years, we have secured a number of “Active Human Beneficial Bacteria” whose therapeutic efficacy has been verified. We conducted research on the intestinal microbiome as well as the respiratory microbiome, and derived development pipelines for various indications including but not limited to inflammatory bowel disease, infectious disease, cardiovascular disease, colorectal cancer, and dyslipidemia. In addition, we have secured a number of isolates with new functions among the strains designated safe by the Ministry of Food and Drug Safety and are developing jointly with domestic and foreign pharmaceutical and food companies.

Establishment of symBioMecollectionTM: Possessing a symbiotic microbiome library according to various lifestyles and health conditions (Over 400 people’s stool and saliva). Source material for identification of new beneficial bacteria. Joint research and development with lead pharmaceutical companies in progress.


Founded in 2016, MicrobiotiX Co., Ltd. is a biotech venture company derived from Yonsei University’s College of Medicine, a top-tier general hospital in Asia. We provide specialized lytic bacteriophage treatment for multi-drug resistant pathogens through synergetic research efforts aimed towards bacteriophages, the microbiome and the phageome. Therapy based on bacteriophages can restore and enhance the life of patients from the grips of gram-negative multi-drug resistant pathogen “super bacteria” infections and metabolic diseases. Our labs are outfitted with the latest technology, and we have amassed a bacteriophage collection with over 300 kinds of bacteriophages and a microbiota bank that has been contributed to over the last 15 years. Currently we are in the process of finalizing a world top 10 state-of-the-art GMP facility to enter the global market. In the area of research, we aim to develop treatment not only for multi-drug resistant pathogens but also for unmet treatment needs for auto-immune and metabolic diseases.

MicrobiotiX has the following core competences: a global leading Bacteriophage collection, an established microbiota bank, and a GMP facility.

We have over 300 kinds of lytic bacteriophages that specifically target 4 out of 6 of the world’s highest risk pathogens by the WHO termed the “ESKAPE” (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp.) pathogens.

BaeRyeo Innovation

Our Nitric Oxide Synthase weakens as we age so the ability to produce Nitric Oxide in our body decreases. Nitric Oxide has been termed the “miracle molecule” because of the benefits it brings to our body. This is why it is widely studied by scientists worldwide, hoping to use it as a form of treatment.

BaeRyeo Innovation is a Jeju company specializing in Nitric Oxide based health ingredients. Started in 2019, we have developed a unique technology where we combine organic fruit and vegetables with our newly created group of microorganisms to produce a new substance which could allow our body to produce Nitric Oxide even with a weak Nitric Oxide Synthase.

Our product, the NODT (Nitric Oxide Donor Transporter) is used as a health supplement which increases Nitric Oxide in the body. Pre-clinical tests have proven that blood vessels of hypertensive rats do not burst even under 100% pressure and this discovery can definitely help people suffering from atherosclerosis which leads to coronary heart diseases, the No. 1 killer in America.

We have several other pre-clinical tests that show significant improvements from hypertension, diabetes, enteritis and enhanced immunity – all these being possible when we have sufficient Nitric Oxide in the body.

Our joint research with America’s Nitric Oxide specialist Dr. Joseph Bauer from Walsh University will begin this September to proceed our studies further in proving the vast capabilities of Nitric Oxide can bring to the human race.


We are building a drug discovery platform with spatial transcriptomics and AI.

Our platform finds targetable molecules (PortraiTARGET), validates the novel drugs based on microscopic distribution and mode of action in the tissue(PortraiDRUG, PortraiMOA), and extracts biomarkers to select the right patients(PortraiTME).

We co-develop the drugs with co-license and provide Platform-as-a-service to pharmaceuticals and biotechs. Radioligand therapy and Antibody-drug conjugate in oncology and brain diseases are therapeutic modalities of interest. AI pathology combined with spatial transcriptomics is our novel approach to make a scalable solution for companion diagnostics.

We’d love to make partnerships with companies in the US to co-develop novel drug assets and collaborations with hospitals to accumulate spatial transcriptomics data with clinical history.

Furthermore, to make us globally competent, the amount of structured datasets from diverse global hospitals would be critical. That’s why we need $10M from this early stage.

We believe that we will revolutionize the drug discovery industry with a data-driven approach and make people healthier.


ABLE Labs provides affordable and easy to use liquid handler that help researchers automate biology experiments. Most biology experiments are done by hand, which could cause various human errors. Introduction of robotics in biology research will mitigate human error, which can could cause major reliability issue.

Competitors in current market lack in affordability and versatility. High price ranging from $150K to $300K, and the fact that these robots require trained professionals to operate, everyday researchers were not able to use them.

Our base model robot NOTABLE is 5 to 10 times cheaper and does not require professional engineer to operate. Despite much lower price, we reached on par pipetting performance including accuracy and precision.

Aside from robotic pipette, ABLE Labs also provide various modules for biology experiment such as temperature controller, thermal cycler, plate shaker and UV and ULPA filter for clean bench setup.

Researchers could operate their personal robot on their lab bench, just like using their own computer. With our user interface, researchers can automate their experiments with just a few simple clicks.

ABLE Labs is consisted with 14 bright and passionate people with different backgrounds including biology, engineering and software. Which ensures precise product targeting and agile operation. Established in 2021, ABLE Labs raised $250K in Pre-Series A funding as of August 2022, and planning to establish US firm in 2023.


Promedius is a spin-off company of Hyundai Seoul Asan Medical Centre.

We develop the medical image reconstruction and diagnostic product (which is named AI-based Software as a Medical Device), and teleradiology platform based on next-generation AI technology.

We have a strong competitive point in the medical imaging physics and AI research fields. Our tech group is world-renowned researchers, which were trained at Asan medical center and KAIST. (Korea’s No.1 hosptial & Tech school)

Our AI solution, PRO CXR: ID can discriminate infectious diseases, such as COVID-19 infection, through CXR images. Also, we have more than 10 proprietary AI models, such as the classification model, de-nosing model, reconstruction model, and generation models.

Recently, we launched a medical AI cloud platform, AIdant, to increase access to medical AI solutions.

We have a strong connection on South Korea and The Republic of Peru. For successful initial market penetration, we looking for partners who can share our value. Our vision is ‘break down barriers to greater health equity by bridging people with AI technology’.

Shinhan Square Bridge (S2 Bridge)

Shinhan Square Bridge (S2 Bridge) Incheon is a platform that supports the growth of startups in cooperation with government agencies and the private sector. S2 Bridge was established as the first public-private Startup Acceleration Platform in South Korea, with the dream of becoming a global startup innovation growth hub.

S2 Bridge is located in Songdo, a city in South Korea recognized as a global business center and bio-cluster. Key partnering organizations include Shinhan Financial Group, a leading global financial group that supports an innovative investment ecosystem, and Celltrion, a global biotech company that supports open innovation opportunities to accelerate promising biotech startups, and Incheon Metropolitan City that actively helps to accelerate the local biotech infrastructure. From the seed to global expansion stage, S2 Bridge focuses on accelerating life science startups based on their innovative technologies.

Shinhan Financial Group has created S² Bridge as a platform to accelerate start-up companies in major Korean cities like Seoul, Incheon, Jeju, and Daegu.


%d bloggers like this: